PCA3 Gene Polymorphism and Prostate Cancer Risk
Author Information
Author(s): Zhou Wu, Chen Zhanguo, Hu Wangqiang, Shen Mo, Zhang Xiaoxia, Li Chengdi, Wen Zhiliang, Wu Xiuling, Hu Yuanping, Zhang Xiaohua, Duan Xiuzhi, Han Xiucui, Tao Zhihua
Primary Institution: The First Affiliated Hospital of Wenzhou Medical College
Hypothesis
Is there a polymorphism in the PCA3 promoter region associated with prostate cancer risk?
Conclusion
The presence of TAAA short tandem repeat polymorphisms in the PCA3 promoter region may increase the risk of prostate cancer in the Chinese population.
Supporting Evidence
- The study identified five polymorphisms and eight genotypes in the PCA3 promoter region.
- Higher TAAA repeat numbers were associated with increased prostate cancer risk.
- The odds ratio for the 11TAAA group was 1.76 compared to the ≤10TAAA group.
- The odds ratio for the ≥12TAAA group was 5.28 compared to the ≤10TAAA group.
- No significant association was found between PCA3 polymorphisms and Gleason score.
Takeaway
This study found that certain genetic variations in a gene related to prostate cancer can make people more likely to develop the disease.
Methodology
The study used PCR-based cloning and sequencing to analyze DNA from blood samples of prostate cancer patients and healthy controls.
Potential Biases
The control group may include individuals who will develop prostate cancer in the future, potentially biasing the results.
Limitations
The study had a small sample size and was conducted in a single regional hospital, which may limit the generalizability of the findings.
Participant Demographics
186 prostate cancer patients and 135 healthy controls, with mean ages of 72.33 and 71.19 years, respectively.
Statistical Information
P-Value
0.01
Confidence Interval
1.07–2.89 for group 11TAAA; 1.76–15.89 for group ≥12TAAA
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website